Certified by Founder Lodge
DiogenX
France - Marseille
START UP
1 Disclosed Funding Rounds $30,056,125
0 Participating Investments
-
Founded date
2020
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| May, 11 ,2023 | Series A | $30,056,125 |
Eli Lilly and Company
Omnes
Boehringer Ingelheim
AdBio partners
JDRF T1D Fund
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
